Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
Shopping Cart: ( empty )
You are here: Home > Journals > SH > SH10001
REVIEW
Contents Vol 8(2)

Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia

Dorota M. Gertig A , Julia M. L. Brotherton A B and Marion Saville A
+ Author Affiliations
- Author Affiliations

A Victorian Cytology Service, PO Box 161, Carlton South, Vic. 3053, Australia.

B Corresponding author. Email: jbrother@vcs.org.au

Sexual Health 8(2) 171-178 https://doi.org/10.1071/SH10001
Submitted: 4 January 2010  Accepted: 21 May 2010   Published: 18 May 2011

Abstract

Accurate estimates of HPV vaccination coverage are critical for determining the proportion of the target female population that is not protected by the vaccine, as well as for monitoring the performance of vaccine delivery programs. The implementation of an HPV vaccination register, either as part of an existing immunisation register or stand-alone, can add substantial benefits to an HPV vaccination program. In Australia, the National HPV Vaccination Program Register supports the HPV vaccination program by providing information to consumers and providers about incomplete courses as well as estimates of vaccination coverage by age and area. Future monitoring of vaccine effectiveness will be facilitated by cross-linking to Pap test registries.

Additional keywords: genital warts, monitoring, papillomavirus.


Acknowledgements

We would like to acknowledge Genevieve Chappell, Karen Peasley and Lesley Rowlands for their work in preparation and provision of the coverage data for this report, and Penny Allen for administrative assistance. The NHVPR is fully funded by the Australian Government and operated by the Victorian Cytology Service Inc.


Addendum


Due to delays in obtaining government approval for release of coverage data from the NHVPR, coverage and program updates have occurred internationally since acceptance of this manuscript. The interested reader may therefore find the following references of supplementary interest:


Sheridan A, White J. Annual HPV vaccine coverage in England in 2009/2010. Report commissioned by UK Department of Health.


Centers for Disease Control and Prevention. National, State, and Local Area Vaccination Coverage among Adolescents Aged 13–17 Years – United States, 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 997–1001.


Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al. The current status of introduction of human papillomavirus vaccination in to national immunisation schedules in Europe: first results of the VENICE 2010 survey. Euro Surveill 2010: 15: pii–19730.


Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H. HPV vaccination in France: Uptake, costs and issues for the National Health Insurance. Vaccine 2011, in press. doi:10.1016/j.vaccine.2011.02.064


References


[1] Brotherton JM. How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine 2008; 26 250–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed | [verified June 2010].

[10] Koulova A,  Tsui J,  Irwin K,  Van Damme P,  Biellik R,  Aguado MT. A brief report: country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006–January 2008. Vaccine 2008; 26 6529–41.
| Crossref | GoogleScholarGoogle Scholar | PubMed | [verified June 2010].

[13] Fairbrother G,  Freed GL,  Thompson JW. Measuring immunization coverage. Am J Prev Med 2000; 19 78–88.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed | [verified June 2010].

[21] Ault KA. Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol 2007; 107 S27–30.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed | [verified June 2010].

[23] Public summary document for quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, injection, 0.5 mL, Gardasil®. Canberra: Australian Government, Department of Health and Ageing. Available online at: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-gardasil-nov06 [verified November 2009].

[24] Hull BP,  Deeks SL,  McIntyre PB. The Australian Childhood Immunisation Register – a model for universal immunisation registers? Vaccine 2009; 27 5054–60.
| Crossref | GoogleScholarGoogle Scholar | PubMed | [verified April 2011].

[29] HPV Vaccination Programme: Provisional data, as submitted by PCTs for First, Second and Third dose vaccine uptake, for the month ending 31 August, 2009. London: National Health Service. Available online at: http://www.immunisation.nhs.uk/publications/HPV_VaccineUptake_Aug2009.pdf [verified June 2010].

[30] Human Papillomavirus (HPV) Vaccine Uptake Annual Survey 2008/09. PCT Immunisation Coordinator User Guide for Determining the Annual Denominator and Vaccine Uptake of the ImFrom Website. Available online at: http://www.immunisation.nhs.uk/publications/HPV_AnnualReturnGuidance_acc.pdf [verified June 2010].

[31] NHS National Service. Child health. Childhood immunisations. Edinburgh: NHS National Service; 2010. Available online at: http://www.isdscotland.org/isd/5921.html [verified June 2010].

[32] Public Health Wales. Vaccine uptake in children in Wales October to December 2009. Public Health Cover Report. Public Health Wales, Vaccine Preventable Disease Programme and Communicable Disease Surveillance Centre. Available online at: http://www.wales.nhs.uk/sites3/Documents/457/Cov09q4%20%5Freport93.pdf [verified June 2010].

[33] Ministry of Health of Quebec. FlashVigie Bulletin Quebecois de vigie et d’entervention en maladie infectieuses, Vol. 4, No. 1, January 2009. Quebec: Ministry of Health; 2009.

[34] Colucci R,  Hryniuk W,  Savage C. Prevention: HPV Vaccination Programs in Canada. Report card on cancer in Canada, Winter 2008–2009. Cancer Advocacy Coalition of Canada 2008; 11 7–8.
[verified June 2010].

[36] Centers for Disease Control and Prevention National, state, and local area vaccination coverage among adolescents aged 13–17 years – United States, 2008. Morb Mortal Wkly Rep 2009; 58 997–1001.